Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Glucagon for hypoglycaemia treatment in type 1 diabetes

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Treatment of modifiable risk factors for foot ulceration in persons with diabetes: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Glucose homeostasis in statin users-The LIFESTAT study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Oral insulin does not alter gut microbiota composition of NOD mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A New Stochastic Approach for Modeling Glycemic Disturbances in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Is reimbursement for alerts and real-time continuous glucose monitoring needed?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

To achieve strict glycaemic control and avoid chronic diabetes complications, individuals with type 1 diabetes (T1D) are recommended to follow an intensive insulin regimen. However, the risk and fear of hypoglycaemia often prevent individuals from achieving the treatment goals. Apart from early insulin suspension in insulin pump users, carbohydrate ingestion is the only option for preventing and treating non-severe hypoglycaemic events. These rescue treatments may give extra calories and cause overweight. As an alternative, the use of low-dose glucagon to counter hypoglycaemia has been proposed as a tool to raise glucose concentrations without adding extra calories. Previously, the commercially available glucagon formulations required reconstitution from powder to a solution before being injected subcutaneously or intramuscularly-making it practical only for treating severe hypoglycaemia. Several companies have developed more stable formulations that do not require the time-consuming reconstitution process before use. As well as treating severe hypoglycaemia, non-severe and impending hypoglycaemia can also be treated with lower doses of glucagon. Once available, low-dose glucagon can be either delivered manually, as an injection, or automatically, by an infusion pump. This review focuses on the role and perspectives of using glucagon to treat and prevent hypoglycaemia in T1D.

OriginalsprogEngelsk
TidsskriftDiabetes - Metabolism: Research and Reviews (Print Edition)
Sider (fra-til)e3409
ISSN1520-7552
DOI
StatusE-pub ahead of print - 25 sep. 2020

Bibliografisk note

© 2020 John Wiley & Sons Ltd.

ID: 61262406